CHRS
Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.
Coherus Oncology, Inc. (CHRS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Momentum (D+). The rating has held at C+ for 10 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | B- (3.1) | C+ (2.8) | D+ (1.5) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | B- (3.0) | B (3.3) | B- (3.0) | D (1.4) | C+ (2.7) | C+ (2.7) |
| 2026-10-28 | B- (3.0) | B (3.3) | B- (3.0) | D+ (1.7) | C+ (2.7) | C+ (2.7) |
| 2026-10-21 | B- (3.0) | B (3.3) | B- (3.0) | D+ (1.8) | C+ (2.6) | C+ (2.7) |
| 2026-10-14 | B- (3.0) | B (3.3) | B- (3.0) | C- (2.0) | C+ (2.6) | C+ (2.8) |